Results 81 to 90 of about 1,419,402 (298)
Baron, Shirley in her home (Box 90, Folder 6) [PDF]
, 1988 Series VIII: Audiocassettes features informal oral histories about the Hebrew Orphan Asylum and its alumni.Digital recordingDigital finding ...
Hebrew Orphan Asylum of New York
core
Establishing a reasonable price for an orphan drug
Cost Effectiveness and Resource Allocation, 2020 Background This paper addresses the question of what a reasonable price for an orphan drug is. The research proposes a way to adjust an established payer/HTA body incremental cost-effectiveness threshold (CET) to take account of differences in patient ...
Mikel Berdud +2 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.External control arms (ECAs) have emerged as important tools to provide benchmark evidence on comparator effectiveness and thereby support regulatory decision making in situations where randomized controlled trials are difficult to conduct. However, how key methodological elements for ECAs are documented and implemented in practice and how residual ...
Suguru Okami, Alexandros Sagkriotis
wiley +1 more source
Finver, Natalie Weinber (Box 90, Folder 15) [PDF]
, 1989 Series VIII: Audiocassettes features informal oral histories about the Hebrew Orphan Asylum and its alumni.Digital recordingDigital finding ...
Hebrew Orphan Asylum of New York
core
Orphan drug: Development trends and strategies
Journal of Pharmacy and Bioallied Sciences, 2010 The growth of pharma industries has slowed in recent years because of various reasons such as patent expiries, generic competition, drying pipelines, and increasingly stringent regulatory guidelines. Many blockbuster drugs will loose their exclusivity in
Aarti Sharma +3 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.When setting the price of cell and gene therapies in Japan, the factors considered include the manufacturing and operating costs of the new drug or a comparator, leading to discrepancies between price and values, in particular those specific to cell and gene therapies.
Akina Takami, Ataru Igarashi
wiley +1 more source
Schorr, Dave (Box 91, Folder 14) [PDF]
, 1977 Series VIII: Audiocassettes features informal oral histories about the Hebrew Orphan Asylum and its alumni.Digital recordingDigital finding ...
Hebrew Orphan Asylum of New York
core
Clinical Pharmacology &Therapeutics, EarlyView.Postmarketing safety surveillance data identify safety issues not identified in preapproval clinical trials. We describe the frequency of new safety issues overall and by labeling section and the relationship of the most commonly added safety issues with the cumulative number of prescriptions dispensed via retail pharmacies.
Ellen Pinnow +14 more
wiley +1 more source
Bogen, Aaron and Louis (Box 90, Folder 10) [PDF]
, 1977 Series VIII: Audiocassettes features informal oral histories about the Hebrew Orphan Asylum and its alumni.Digital recordingDigital finding ...
Hebrew Orphan Asylum of New York
core
Do investors value the FDA orphan drug designation?
Orphanet Journal of Rare Diseases, 2017 Background The Orphan Drug Act is an important piece of legislation that uses financial incentives to encourage the development of drugs that treat rare diseases.
Kathleen L. Miller
doaj +1 more source